Glutathione is sold for lighter, brighter skin as a cream, a capsule and an intravenous drip, often under one set of promises. The evidence does not work that way: each route has its own small literature, and they do not add up to one claim. This page counts them separately. It reports what was measured and does not recommend any product, route or amount. Where a dose appears, it is a trial's protocol, given with its source.
What glutathione is
Glutathione is a tripeptide of glutamate, cysteine and glycine (PubChem CID 124886, about 307 g/mol). It is made in every cell and is the body's main intracellular antioxidant. Peptide Lexicon's glutathione entry covers the molecule. This page covers the skin question.
Its link to skin colour runs through melanin. In laboratory work glutathione pushes pigment cells away from dark eumelanin towards lighter phaeomelanin and damps the enzyme tyrosinase. That mechanism is why it is sold for lightening. What follows is whether the effect shows up in people, and by which route.
The census, and why most hits are not trials of glutathione
On 23 September 2026, PubMed's "randomized controlled trial"[pt] filter returned 45 records for glutathione with a skin, melanin, lightening or pigment term. Read one by one, most do not give glutathione to anyone. They measure it as a blood or tissue marker in trials of something else: botanical drinks, pearl powder, vitamin E in dogs, burn-unit trace elements. Six of the 45 give glutathione for a skin endpoint — and only two of those test it on skin colour against its own placebo (Arjinpathana 2012, Wahab 2021). The other four give a derivative (S-acyl glutathione), a cystine–glutathione capsule, a glutathione–anthocyanin mix during radiotherapy, or an injectable mix with hyaluronate, vitamin C and tranexamic acid for dark circles. Counting the 45 as "glutathione trials" is the most common way this literature gets overstated.
The two systematic reviews give the cleaner count:
| Route | What the reviews found | Typical measure |
|---|---|---|
| Oral | Five randomized placebo-controlled trials and one open-label study; 250 mg once or twice daily, or 500 mg once daily; melanin index reduced against placebo (Sarkar 2025) | Melanin index by skin meter |
| Topical | 2% glutathione or 2% oxidised glutathione; 0.5% beat 0.1% and placebo in one comparison; effects local to the treated area (Sarkar 2025; Dilokthornsakul 2019) | Melanin index, often split-face |
| Topical + oral | One 46-person trial: the combination gave the lowest melanin index (Wahab 2021) | Mexameter and chromameter over 8 weeks |
| Intravenous | One placebo-controlled study: 6/16 improved vs 3/16, p = 0.054 (Sarkar 2025) | Not significant |
Oral: the most trials, and small effects
The most-cited oral trial is Arjinpathana 2012. Sixty medical students in Bangkok took 500 mg a day in two doses, or placebo, for four weeks. The melanin index fell at all six measured sites in the glutathione group. It beat placebo significantly at two of the six: the right side of the face (p = 0.021) and the sun-exposed left forearm (p = 0.036). The authors called it lightening "in a small number of subjects" and wrote that long-term safety "has not been established".
That shape recurs. The 2019 review by Dilokthornsakul and colleagues found four eligible studies. Oral glutathione at 500 mg a day and 2% oxidised glutathione cream both lowered the melanin index on sun-exposed skin. Neither did anything significant on sun-protected skin. The reviewers called the evidence "still inconclusive due to the quality of included studies and inconsistent findings". An effect seen on the face and forearm but not the inner arm fits best with slower re-tanning rather than a change in baseline skin tone. The trials were not designed to tell those two apart, and this is our reading, not their finding.
Topical: local, modest, and a size argument that only goes halfway
At about 307 g/mol, glutathione sits well under the roughly 500-dalton line (Bos and Meinardi, 2000) often used as a rough limit for what can cross the skin barrier. Our copper peptides guide uses the same yardstick. Being small enough is necessary but not sufficient. The barrier favours molecules that are somewhat fat-soluble, and glutathione is strongly water-soluble. The trials sidestep the question: they measure skin colour, not how much glutathione reached a pigment cell.
The topical trials report small, local changes: 2% creams, often one side of the face against the other. One trial tested a related cream, S-acyl glutathione 2%, against UVB redness rather than colour (Grandi 2019). That is a different endpoint, and it is a reminder that "glutathione cream" is not one ingredient. For the antioxidant pairing most often sold beside it, see our page on peptides and vitamin C.
Intravenous: the route with the least evidence and the most warnings
The drip is the most expensive route and the least supported. The 2025 review found one placebo-controlled IV study. In it, 6 of 16 treated participants improved against 3 of 16 on placebo, and the difference was not significant (p = 0.054). The reviewers' conclusion is blunt: "IV glutathione is contraindicated due to lack of efficacy and side effects."
Regulators got there first. In September 2015, FDA warned consumers that it "has not approved any injectable drugs for skin whitening or lightening", naming glutathione among the usual ingredients of such products. An FDA pharmacist was quoted: "You're essentially injecting an unknown substance into your body." The warning adds the risks of the injection itself, such as infection and contamination, to those of the product. For the wider context of peptides sold by injection for skin, see our glow stack guide.
What the marketing claims and what the trials measured
"Whitening" and "brightening" pages show photographs. The trials measured a melanin index: a meter's reading of light reflected from the skin, reported as a change in units on that scale. A statistically significant fall on that scale is a real measurement. It is not the same thing as a visible change in complexion. The 2025 review also describes both the oral and the topical results as "unsustainable".
What would change this page
A longer trial, beyond a few months, with a follow-up after stopping. A trial that measures sun-protected and sun-exposed skin under controlled sun exposure. A properly powered IV study. Any of these would be reported here, dated. For how peptides act on skin more broadly, see what peptides do for skin.
Sources
- Sarkar R, Yadav V, Yadav T, et al. Glutathione as a skin-lightening agent and in melasma: a systematic review. Int J Dermatol 2025;64(6):992-1004. PMID 39444151.
- Dilokthornsakul W, Dhippayom T, Dilokthornsakul P. The clinical effect of glutathione on skin color and other related skin conditions: a systematic review. J Cosmet Dermatol 2019;18(3):728-737. PMID 30895708.
- Arjinpathana N, Asawanonda P. Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study. J Dermatolog Treat 2012;23(2):97-102. PMID 20524875.
- Wahab S, Anwar AI, Zainuddin AN, et al. Combination of topical and oral glutathione as a skin-whitening agent: a double-blind randomized controlled clinical trial. Int J Dermatol 2021;60(8):1013-1018. PMID 33871071.
- Grandi V, et al. S-acyl glutathione 2% cream vs placebo against UVB-induced erythema. G Ital Dermatol Venereol 2019. PMID 28399620.
- Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 2000. PMID 10839713.
- U.S. FDA consumer warning on injectable skin-lightening products, 14 September 2015, as reported by Healio; FDA's own page did not load for us on 2026-09-23.
- PubChem, glutathione, CID 124886.
- PubMed E-utilities census, 2026-09-23:
glutathione[tiab]with skin/melanin/lightening/whitening/pigment terms and"randomized controlled trial"[pt](45 records, each read).